| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Programmed death 1 (PD-1), and its associated ligand (PD-L1) checkpoint blockade immunotherapy caused a new paradigm shift in treatment for patients with non-small cell lung cancer (NSCLC). Appropriate patient selection is critically important. To identify predictive biomarkers immune checkpoint inhibitors, we comprehensively analyzed previously reported predictive biomarkers such as smoking status, driver oncogene alterations, PD-L1 expression, MSI and tumor immune microenvironment, and clarified the reciprocal relationship among them. We showed that MSI is a rare event in lung adenocarcinoma. MSI cannot be used as a biomarker to predict the treatment effect of immune checkpoint inhibitors for lung adenocarcinoma. NSCLCs can be divisible into immunoreactive and non-immunoreactive tumors. The prognostic value differs according to the immunomodulatory target and driver oncogene status.
|
